States Sue To Block 23andMe From Selling Genetic Data Without Consent

Twenty-seven states and the District of Columbia have filed a lawsuit to prevent the sale of personal genetic data by 23andMe without customer consent. The lawsuit, filed in bankruptcy court on Monday (June 9), aims to block the sale of sensitive data as the biotechnology company faces financial difficulties.

Oregon Attorney General Dan Rayfield emphasized the importance of protecting personal genetic information. "Biological samples, DNA data, health-related traits, and medical records are too sensitive to be sold without each person's express, informed consent," he stated in a news release. Customers should have control over their personal information, which cannot be treated like ordinary property.

Founded in 2006, 23andMe offers saliva-based DNA testing kits to help customers learn about their ancestry and health. However, the company has struggled financially since going public in 2021. In March, it laid off 40% of its staff and filed for Chapter 11 bankruptcy protection in the Eastern District of Missouri, raising concerns about the safety of customer data.

Regeneron Pharmaceuticals has expressed interest in purchasing 23andMe for $256 million. The company has stated that it will comply with 23andMe's privacy policies and applicable laws, ensuring that customer data is processed according to existing consents and privacy policies.